Balance Sheet

Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Apyx Medical (APYX) Change in Acquisitions & Divestments (2018 - 2019)

Apyx Medical filings provide 2 years of Change in Acquisitions & Divestments readings, the most recent being $40.9 million for Q2 2019.

On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $40.9 million in Q2 2019 year-over-year; TTM through Mar 2020 was $40.9 million, a 37.68% decrease, with the full-year FY2019 number at $80.7 million, up 213.4% from a year prior.
Change in Acquisitions & Divestments hit $40.9 million in Q2 2019 for Apyx Medical, up from $39.8 million in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $40.9 million in Q2 2019 to a low of $25.8 million in Q4 2018.